Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rVSV∆G-SEBOV-GP
- Development stage
- Unknown
- Lead developer
- International AIDS Vaccine Initiative
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
rVSV∆G-SEBOV-GP is a recombinant viral vector vaccine candidate developed by IAVI in partnership with GSK for the prevention of Sudan virus disease (SVD). The vaccine utilizes a replication-competent vesicular stomatitis virus (rVSV) platform, similar to the technology used in the approved Ervebo vaccine for Zaire ebolavirus. In this construct, the native glycoprotein (G) of the VSV vector is deleted and replaced with the glycoprotein (GP) of the Sudan ebolavirus (SEBOV). Upon administration, the vector expresses the SEBOV-GP antigen to induce protective humoral and cellular immune responses against the Sudan virus. The candidate is currently undergoing Phase 1 clinical evaluation to assess its safety and immunogenicity.
- Other names
- Sudan ebolavirus glycoprotein (SEBOV-GP)-viral vector vaccine (rVSV-based)rVSV-Sudan virus vaccinerVSV-SEBOV-GP
02
Targets
Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on rVSV∆G-SEBOV-GP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rVSV∆G-SEBOV-GP.